OptiNose Stock Scheduled to Reverse Split on Tuesday, December 31st (NASDAQ:OPTN)

OptiNose, Inc. (NASDAQ:OPTN)’s stock is scheduled to reverse split on Tuesday, December 31st. The 1-15 reverse split was announced on Thursday, December 26th. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, December 30th.

OptiNose Stock Up 10.3 %

NASDAQ OPTN opened at $0.42 on Friday. OptiNose has a 52 week low of $0.32 and a 52 week high of $2.10. The firm has a market capitalization of $63.35 million, a price-to-earnings ratio of -1.50 and a beta of -0.16. The company has a fifty day moving average of $0.57 and a two-hundred day moving average of $0.83.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the stock. HC Wainwright restated a “buy” rating and issued a $5.00 target price on shares of OptiNose in a report on Wednesday, November 13th. Piper Sandler decreased their price objective on shares of OptiNose from $3.00 to $1.00 and set an “overweight” rating for the company in a research note on Wednesday, November 13th.

Institutional Trading of OptiNose

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. FMR LLC boosted its stake in shares of OptiNose by 3.2% during the third quarter. FMR LLC now owns 16,541,849 shares of the company’s stock valued at $11,083,000 after purchasing an additional 518,610 shares during the period. Great Point Partners LLC lifted its holdings in OptiNose by 56.2% during the 2nd quarter. Great Point Partners LLC now owns 13,727,097 shares of the company’s stock valued at $14,276,000 after buying an additional 4,940,779 shares in the last quarter. Nantahala Capital Management LLC boosted its position in OptiNose by 442.3% in the 2nd quarter. Nantahala Capital Management LLC now owns 13,418,740 shares of the company’s stock valued at $14,425,000 after buying an additional 10,944,444 shares during the period. Rosalind Advisors Inc. grew its stake in OptiNose by 9.8% in the 3rd quarter. Rosalind Advisors Inc. now owns 8,287,503 shares of the company’s stock worth $5,553,000 after acquiring an additional 740,355 shares in the last quarter. Finally, Stonepine Capital Management LLC increased its position in shares of OptiNose by 142.1% during the third quarter. Stonepine Capital Management LLC now owns 5,688,590 shares of the company’s stock worth $3,811,000 after acquiring an additional 3,338,580 shares during the period. Hedge funds and other institutional investors own 85.60% of the company’s stock.

About OptiNose

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.